Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEN 
Compugen (CGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 220.67% | Avg. Invested days 42 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.62M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 4 | Beta 2.55 | 52 Weeks Range 1.13 - 2.66 | Updated Date 07/12/2025 |
52 Weeks Range 1.13 - 2.66 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.27% | Operating Margin (TTM) -367.56% |
Management Effectiveness
Return on Assets (TTM) -8.07% | Return on Equity (TTM) -24.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58917232 | Price to Sales(TTM) 5.79 |
Enterprise Value 58917232 | Price to Sales(TTM) 5.79 | ||
Enterprise Value to Revenue 2.13 | Enterprise Value to EBITDA -19.16 | Shares Outstanding 93513000 | Shares Floating 90420522 |
Shares Outstanding 93513000 | Shares Floating 90420522 | ||
Percent Insiders 2.12 | Percent Institutions 18.11 |
Upturn AI SWOT
Compugen
Company Overview
History and Background
Compugen was founded in 1993. Initially focused on computational drug discovery, it has evolved into a clinical-stage drug discovery and development company focused on immuno-oncology.
Core Business Areas
- Immuno-Oncology: Compugen focuses on discovering and developing novel therapeutics that harness the immune system to fight cancer, particularly targeting previously undiscovered drug targets within the tumor microenvironment.
Leadership and Structure
Compugen is led by a CEO and has a board of directors. The company's structure includes research and development, clinical development, and business development teams.
Top Products and Market Share
Key Offerings
- COM701: COM701 is a first-in-class antibody targeting PVRIG, a novel immune checkpoint target. It is in clinical development for various solid tumors. No specific market share data is available. Competitors include companies developing checkpoint inhibitors.
- BAY 1905254 (formerly COM902): BAY 1905254 (formerly COM902) is a monoclonal antibody targeting TIGIT. Bayer is developing this product under a licensing agreement with Compugen. No specific market share data is available. Competitors include companies developing TIGIT inhibitors.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by the increasing prevalence of cancer and the potential of immunotherapy to provide durable responses. It is highly competitive.
Positioning
Compugen is positioned as an innovator in the immuno-oncology space, focused on discovering and developing first-in-class therapies targeting novel immune checkpoints. Its competitive advantage lies in its target discovery platform.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is estimated to be in the tens of billions of dollars. Compugen is positioned to capture a portion of this market through its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Novel Target Discovery Platform
- First-in-class therapeutic candidates
- Strategic partnerships with major pharmaceutical companies
- Strong scientific expertise
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Limited commercialization experience
- Dependence on partnerships for late-stage development
Opportunities
- Expanding clinical trials to new indications
- Securing additional partnerships and licensing agreements
- Advancing pipeline candidates towards commercialization
- Potential for breakthrough therapies in unmet medical needs
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Market access challenges
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
- GILD
Competitive Landscape
Compugen faces competition from larger pharmaceutical companies with established immuno-oncology therapies. Its competitive advantage lies in its novel target discovery platform and first-in-class therapeutic candidates. The above listed companies may compete in the same market with varying degrees of overlap in specific indications, research areas, or collaborations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by licensing agreements and milestone payments, but with high operating costs related to R&D.
Future Projections: Future growth depends on successful clinical trial outcomes and commercialization of pipeline candidates. Analyst estimates would be needed.
Recent Initiatives: Recent initiatives include advancing COM701 and BAY 1905254 through clinical trials and seeking additional partnerships.
Summary
Compugen is a clinical-stage immuno-oncology company with a novel target discovery platform. Its strength lies in its innovative pipeline and partnerships. However, it faces risks associated with clinical trial outcomes and competition from established players. Future success depends on progressing its pipeline and securing further partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Compugen Corporate Website
- SEC Filings (10-K, 10-Q)
- Company Presentations
- Analyst Reports (when available)
Disclaimers:
This analysis is based on publicly available information and general market knowledge. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compugen
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2000-08-11 | CEO, President & Director Dr. Anat Cohen-Dayag Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://cgen.com |
Full time employees 74 | Website https://cgen.com | ||
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.